Skip to content

Comparative study of aerosol inhalation of dexmedetomidine esketamine and aerosol inhalation of dexmedetomidine fentanyl in the diagnosis and treatment of painless bronchoscopy

Comparative study of aerosol inhalation of dexmedetomidine esketamine and aerosol inhalation of dexmedetomidine fentanyl in the diagnosis and treatment of painless bronchoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079003
Enrollment
Unknown
Registered
2023-12-22
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless bronchoscopy diagnosis and treatment

Interventions

Dexmedetomidine + fentanyl group:Atomization inhalation of dexmedetomidine combined with fentanyl+ Lidocaine aerosol inhalation
Dexmedetomidine + esketamine group:Dexmedetomidine combined with esketamine aerosol inhalation+ Lidocaine aerosol inhalation
Dexmedetomidine group:Atomization inhalation of dexmedetomidine+ Lidocaine aerosol inhalation
placebo group:Lidocaine aerosol inhalation

Sponsors

First Affiliated Hospital of Gannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. ASA grade I-III ; 2.Patients aged 18-80 years old, regardless of gender and race, were scheduled for painless fiberoptic bronchoscopy ; 3.The diagnosis and treatment time is less than 1 hour; 4. Voluntary subjects, signed informed consent, in line with medical ethics;

Exclusion criteria

Exclusion criteria: 1. Drug, alcohol and substance abusers ; 2. patients who had used psychotropic drugs or participated in clinical studies of other drugs within 3 months before enrollment ; 3. Bmi > 30Kg / M2; 4. Patients with liver and kidney dysfunction or recent active hepatitis ; 5. Patients with a history of allergies to the drugs used in the study ; 6. Pregnancy, lactation and short-term pregnancy plan ; 7. Patients with estimated intraoperative blood loss greater than 20 % of the total ; 8. Controlled hypotension during operation ; 9. severe dehydration and severe malnutrition ; 10. the presence of any nasal lesions or nasal congenital abnormalities ; 11. Those without autonomy, mental disorders or other reasons do not cooperate ; 12. patients with severe diseases such as heart, brain, blood system and malignant tumors ;

Design outcomes

Primary

MeasureTime frame
Bronchoscopic sedation comprehensive score;Alertness / sedation score;Incidence and frequency of adverse reactions;Postoperative evaluation of medical staff and patients;Preoperative and postoperative hospital anxiety and depression scale;Preoperative and postoperative sore throat score;

Secondary

MeasureTime frame
Blood pressure saturation;Heart rate;Mean arterial pressure;Respiratory rate;The total amount of lidocaine and propofol and the use of remedial drugs were used;Time of diagnosis, treatment, awakening and leaving the room;

Countries

China

Contacts

Public ContactChen Li

First Affiliated Hospital of Gannan Medical College

2496700057@qq.COM+86 157 2775 2168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026